In an era where mental health disorders such as depression and anxiety are among the leading causes of disability worldwide, the search for innovative treatments is more pressing than ever. The 7th Neuropsychiatric Drug Development Summit, held in Boston from September 24-26, 2024, highlighted an important breakthrough in this field. At the center of the event’s attention was Enveric Biosciences (NASDAQ: ENVB), a biotechnology company committed to developing novel neuroplastogenic small-molecule therapeutics. Enveric presented compelling preclinical data for their lead drug candidate, EB-003, a non-hallucinogenic, neuroplastogenic analog of N,N-Dimethyltryptamine (DMT), designed to treat anxiety and depression without the hallucinogenic effects commonly associated with traditional DMT-based therapies.
